Addex Therapeutics Ltd
ADXN
$6.07
$0.132.19%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 300.00 | 37.20K | -- | -- | 1.70K |
| Total Other Revenue | 19.50K | 24.80K | 44.10K | 79.00K | 0.00 |
| Total Revenue | 19.80K | 62.00K | 44.10K | 79.00K | 1.70K |
| Cost of Revenue | 66.10K | 285.40K | 284.20K | 173.60K | 74.40K |
| Gross Profit | -46.30K | -223.40K | -240.10K | -94.60K | -72.70K |
| SG&A Expenses | 929.10K | 646.90K | 648.30K | 579.80K | 434.70K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 995.20K | 932.30K | 932.60K | 753.40K | 509.20K |
| Operating Income | -975.40K | -870.30K | -888.50K | -674.40K | -507.40K |
| Income Before Tax | -2.30M | -1.97M | -2.37M | -1.64M | -1.35M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.30M | -1.97M | -2.37M | -1.64M | -1.35M |
| Earnings from Discontinued Operations | -4.30K | -- | 142.70K | -- | -18.10K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.30M | -1.97M | -2.23M | -1.64M | -1.37M |
| EBIT | -975.40K | -870.30K | -888.50K | -674.40K | -507.40K |
| EBITDA | -975.30K | -870.10K | -885.90K | -672.00K | -480.30K |
| EPS Basic | -0.02 | -0.02 | -0.02 | -0.02 | -0.01 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | -0.02 | -0.02 | -0.02 | -0.02 | -0.01 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 117.88M | 112.68M | 100.52M | 98.35M | 98.33M |
| Average Diluted Shares Outstanding | 117.88M | 112.68M | 100.52M | 98.35M | 98.33M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |